Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Blood (2019) 134 (Supplement_1): 468.

https://doi.org/10.1182/blood-2019-128513

Published: 2019

Journal Articles

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Stephen Reeder, BSc, Clare Coveney, PhD, Sergio Rutella, MDPhDFRCPath

Blood (2019) 134 (Supplement_1): 2726.

https://doi.org/10.1182/blood-2019-124717

Published: 2019

Journal Articles

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Sabine Kayser, MD, Michelle A Elliott, MD, Marlise Luskin, MDMS, Andrew M. Brunner, MD, Michael Kramer, M.Sc., Zdenek Racil, MD, Zuzana Sustkova, MD, Petr Cetkovsky, MD MBA, PhD, Jan Novak, MD PhD, Friedrich Stoelzel, MD, Christian Thiede, MD, Carsten Müller-Tidow, MD, Uwe Platzbecker, Christoph Röllig, MD MSC, Richard F. Schlenk, MD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 2693.

https://doi.org/10.1182/blood-2019-125317

Published: 2019

Journal Articles

Critical Role of Jumonji Domain of JMJD1C in AML Leukemogenesis

Jesus Izaguirre-Carbonell, PhD, Christiansen Luke, Robert Burns, PhD, Jesse Schmitz, Chenxuan Li, Rebekah Mokry, Theresa Bluemn, Yongwei Zheng, Demin Wang, PhD, Nan Zhu, PhD

Blood (2018) 132 (Supplement 1): 2599.

https://doi.org/10.1182/blood-2018-99-110463

Published: 2018

Journal Articles

Crosstalk between the IGF1 and CXCL12 Pathways Defines Objective Responses to the Farnesyl Transferase Inhibitor Tipifarnib in AML and PTCL Patients

Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Vishnu Mishra, PhD, Matthew R Janes, PhD, Linda Kessler, BA

Blood (2018) 132 (Supplement 1): 5349.

https://doi.org/10.1182/blood-2018-99-116969

Published: 2018

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Blood (2018) 132 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2018-99-118383

Published: 2018

Journal Articles

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Thomas E. Witzig, MD, Lubomir Sokol, MD PhD, Eric D Jacobsen, MD, Won-Seog Kim, MD PhD, Francine M. Foss, MD, Ranjana H. Advani, MD, Jose Maria Roncero Vidal, MD, Ana Marin Niebla, PhD, Antonia Rodriguez Izquierdo, PhD, Raquel De Ona Navarrete, MD, Fátima de la Cruz Vicente, MD, Dolores Caballero, MD, Rufino Mondejar, PhD, Miguel A. Piris, PhD MD, Robert Curry, BA, MBA, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD

Blood (2018) 132 (Supplement 1): 2937.

https://doi.org/10.1182/blood-2018-99-116277

Published: 2018

Journal Articles

Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines

Ruth Alonso Alonso, PhD, Rufino Mondejar García, PhD, Jose Pedro Vaqué Díez, PhD, Nuria García Díaz, PhDcandidate, Cristina Pérez Menéndez, PhD, Francis Burrows, PhD, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD, Miguel A. Piris, PhD MD

Blood (2018) 132 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2018-99-118291

Published: 2018

Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD

Blood (2017) 130 (Supplement 1): 4227.

https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227

Published: 2017

Journal Articles

Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)

Mrinal M. Patnaik, MDMBBS, David A Sallman, MD, Mikkael A. Sekeres, MD MS, Selina Luger, MD FRCPC, Rafael Bejar, MD PhD, Gabriela S. Hobbs, MD, Amy E. DeZern, MD, James Bolognese, PhD, Mary Traynor, RN, Vishnu Mishra, PhD, David Wages, MD PhD, Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Eric Padron, MD

Blood (2017) 130 (Supplement 1): 2963.

https://doi.org/10.1182/blood.V130.Suppl_1.2963.2963

Published: 2017

Journal Articles

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma

Thomas E Witzig, MD, Lubomir Sokol, MD PhD, Eric Jacobsen, MD, Ranjana H. Advani, MD, Francine M Foss, MD, Rufino Mondejar, PhD, Miguel Angel Piris, PhDMD, James Bolognese, PhD, Francis Burrows, PhD, Linda Kessler, BA, Karen Bracken, MHS, Vishnu Mishra, PhD, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD

Blood (2017) 130 (Supplement 1): 2788.

https://doi.org/10.1182/blood.V130.Suppl_1.2788.2788

Published: 2017

Journal Articles

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Matthew R Janes, PhD, Linda Kessler, BA, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 3957.

https://doi.org/10.1182/blood.V130.Suppl_1.3957.3957

Published: 2017

Journal Articles

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation

Diego Coutinho, BS, Abdullah Mahmood Ali, PhD, Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Karen Bracken, MHS, Joseph G. Jurcic, MD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 1677.

https://doi.org/10.1182/blood.V130.Suppl_1.1677.1677

Published: 2017

Journal Articles

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

Abby Statler, MPH, MA, Megan Othus, PhD, Harry P. Erba, MD PhD, Thomas R. Chauncey, MD PhD, Jerald P. Radich, MD, Steven E. Coutre, MD, Anjali S. Advani, MD, Sucha Nand, MD, Farhad Ravandi, MD, Sudipto Mukherjee, MD, PhD, M.P.H., Mikkael A. Sekeres, MD MS

Blood (2016) 128 (22): 4002.

https://doi.org/10.1182/blood.V128.22.4002.4002

Published: 2016

Journal Articles

Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902

Selina Luger, MD, Victoria X Wang, Elisabeth Paietta, PhD, Rhett P. Ketterling, MD, Witold Rybka, MD, Hillard M. Lazarus, MD, Mark R Litzow, MD, Jacob M. Rowe, MD, Richard A. Larson, MD, Frederick R Appelbaum, MD, Martin S. Tallman, MD

Blood (2015) 126 (23): 1308.

https://doi.org/10.1182/blood.V126.23.1308.1308

Published: 2015

Journal Articles

MLL - AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia

Elena Manara, Emma Baron, Claudia Tregnago, Sanja Aveic, Valeria Bisio, Silvia Bresolin, Riccardo Masetti, Franco Locatelli, Giuseppe Basso, Martina Pigazzi

Blood (2014) 124 (2): 263–272.

https://doi.org/10.1182/blood-2013-09-525741

Published: 2014

Includes: Supplemental data

Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Jeffrey E Lancet, MD, Eric Feldman, MD, Matthew C Foster, MD, Ivana Gojo, MD, Olatoyosi Odenike, MD, Rami S. Komrokji, MD, Roger Strair, MD, PhD, Scott H. Kaufmann, MD, PhD, Roland Knoblauch, MD, PhD, J. D. Karkera, PhD, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 1508.

https://doi.org/10.1182/blood.V120.21.1508.1508

Published: 2012

Journal Articles

R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission

Selina Luger, MD, Lynette Zickl, MS, Elisabeth Paietta, PhD, Rhett P Ketterling, MD, Hillard M Lazarus, MD, Witold Rybka, MD, Mark R Litzow, MD, Jacob M Rowe, MD, Richard A. Larson, MD, Martin S. Tallman, MD

Blood (2012) 120 (21): 676.

https://doi.org/10.1182/blood.V120.21.676.676

Published: 2012

Journal Articles

Two genes, tipifarnib, and AML

Rosa Ruchlemer

Blood (2012) 119 (1): 2–3.

https://doi.org/10.1182/blood-2011-10-386490

Published: 2012

Journal Articles

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Blood (2012) 119 (1): 55–63.

https://doi.org/10.1182/blood-2011-08-370825

Published: 2012

Includes: Supplemental data

NARROW

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Critical Role of Jumonji Domain of JMJD1C in AML Leukemogenesis

Crosstalk between the IGF1 and CXCL12 Pathways Defines Objective Responses to the Farnesyl Transferase Inhibitor Tipifarnib in AML and PTCL Patients

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902

MLL - AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission

Two genes, tipifarnib, and AML

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only